Is Elafibranor a targeted drug or a traditional chemotherapy drug?

Elafibranor (Elafibranor) is a new type of targeted drug that does not belong to traditional chemotherapy drugs. Its mechanism of action is to activate peroxisome proliferator-activated receptor (PPAR) alpha and delta dual agonists. By regulating lipid metabolism, insulin sensitivity and inflammatory response, it has the effect of treating metabolic or inflammatory diseases such as steatohepatitis (NASH) and primary biliary cholangitis (PBC). This type of mechanism clearly shows that it is a typical target therapy drug.

Unlike traditional chemotherapy drugs, irafibratenol does not work by directly killing cells or inhibiting cell division. Traditional chemotherapy drugs often lack targeting. While killing tumor cells, they can also cause serious damage to normal cells, thus causing obvious side effects. Ilafibratenol has strong targeting properties, can regulate specific signaling pathways, improve liver function, has relatively few side effects and is safer.

In terms of therapeutic effect, irafibratenol has shown certain efficacy in clinical studies on diseases such as non-alcoholic steatohepatitis and PBC. Multiple clinical trials have shown that the drug can significantly reduce liver enzyme levels, improve liver fibrosis scores, and delay disease progression. It is especially suitable for patients with chronic liver diseases for which there are currently no extensive treatments, so it has attracted much attention.

To sum up, irafibratenol belongs to the category of targeted drugs and is a metabolic disease modulator developed based on molecular targets. Its precise mechanism of action is different from traditional chemotherapy, with higher selectivity and better tolerance. It has broad application prospects in the treatment of fatty liver disease and biliary diseases in the future. For patients, this targeted treatment not only improves the treatment effect, but also significantly improves the quality of life.

Reference materials:https://www.drugs.com